Hemoglobinopathies: Clinical Trials

73 trials for Hemoglobinopathies, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

39 completed, 10 unknown, 6 terminated, 6 withdrawn. 73 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 473Completed 39, Unknown 10, Terminated 6, Withdrawn 6, Recruiting 5, Active not recruiting 3, Not yet recruiting 3, Enrolling by invitation 1

Follow Hemoglobinopathies: new trials by email Literature Review of Hemoglobinopathies trials Research Report on Hemoglobinopathies

Trials (filtered) newest first · largest first

All 73 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis
Group 02 Paracetamol + Morphine + Ketamine, Group 01 Control: Paracetamol + Morphine, Group 03 : Paracetamol + Morphine + Nefopam - Sickle Cell Disease, Vaso-occlusive Crisis
Phase 4Not yet recruitingAssistance Publique - Hôpitaux de Paris4002026-10-012026-09-18
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
Prophylactic Transfusion Intervention group: Transfusion, Control group - Sickle Cell Disease, Pregnancy Related
Phase 4WithdrawnEmory University2026-09-012026-10-19
Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis
Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm) - Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD)
Phase 4Not yet recruitingUniversity of Mississippi Medical Center4002026-08-012026-07-06
Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire
Gazelle-Multispectral point of care testing for newborn sickle cell disease screening; and initiation of early comprehensive clinical interventions - Sickle Cell Disease (SCD)
Phase 4RecruitingSwiss Tropical & Public Health Institute1202026-07-272026-10-05
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
Depot medroxyprogesterone acetate (DMPA) - Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Phase 4RecruitingUniversity of Pennsylvania652025-06-262026-11-05
Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)
PK-optimized oral hydroxyurea at MTD until 15 years of age. - Sickle Cell Anemia (HbSS), Sickle-β0-thalassemia (HbSβ0)
Phase 4RecruitingChildren's Hospital Medical Center, Cincinnati502024-12-192025-09-16
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
Ketorolac - Sickle Cell Disease, Sickle Cell Crisis
Phase 4Not yet recruitingChildren's Blood and Cancer Center at Dell Children's Medical Center1022024-09-302024-08-30
Effects of Hydroxyurea and Metformin in Transfusion Dependent Beta-Thalassemia
Tablet Metformin (Group A), Tablet Hydroxyurea (Group B) - Transfusion Dependent Beta-thalassemia
Phase 4CompletedBahria University962024-09-162026-04-28
Stroke Prevention in Nigeria 2 Trial
Hydroxyurea - Sickle Cell Disease, Stroke
Phase 4RecruitingVanderbilt University Medical Center2202024-08-052026-03-05
Voxelotor Brain Oxygenation and Neurocognitive Study
Voxelotor Oral Tablet - Sickle Cell Disease
Phase 4WithdrawnPfizer2023-08-092024-08-09
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
Nexplanon 68 MG Drug Implant - Sickle Cell Disease
Phase 4Active not recruitingUniversity of Pennsylvania222023-08-022026-06-12
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Mitapivat - Pyruvate Kinase Deficiency, Anemia, Hemolytic
Phase 4Enrolling by invitationAgios Pharmaceuticals, Inc.552023-07-062026-10-28
A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India
Luspatercept - Anemia
Phase 4Active not recruitingBristol-Myers Squibb852023-06-052026-08-31
Clonidine With Morphine in Patient Controlled Analgesia Pump in Vaso-Occlusive Crisis in Sickle Cell Disease Patient
Clonidine - Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease
Phase 4UnknownCentre Hospitalier Universitaire Saint Pierre402023-04-252023-05-08
The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study
Luspatercept Injectable Product - Thalassemia Major, Transfusion-dependent Anemia
Phase 4UnknownSun Yat-sen University202022-07-012022-07-18
Glutamine Role in Preventing Vaso-occlusive Crisis Among SCD Patients
L-Glutamine, Oral Powder for Reconstitution, Standard of care - Sickle Cell Disease
Phase 4CompletedAin Shams University602022-01-042024-01-09
Ketamine Infusion for Sickle Cell Pain Crisis
Ketamine, Pain management - Anemia; Sickle-Cell, With Crisis, Acute Pain
Phase 4WithdrawnDuke University2022-01-012022-01-14
Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age
Trumenba - Meningococcal Vaccine
Phase 4CompletedPfizer532021-08-182024-10-16
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
crizanlizumab - Sickle Cell Disease (SCD)
Phase 4CompletedNovartis Pharmaceuticals1402021-07-142025-09-26
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Crizanlizumab - Sickle Cell Disease
Phase 4RecruitingNovartis Pharmaceuticals1302021-06-102026-06-08

Showing 20 of 73. Sign in to see all of them.

Narrower conditions

Anemia, Sickle Cell (38)  ·  Thalassemia (17)  ·  beta-Thalassemia (17)  ·  Iron Overload (10)  ·  Vaso-Occlusive Crises (10)  ·  Agnosia (3)  ·  Anemia (3)  ·  Hepatitis C (3)  ·  Myelodysplastic Syndromes (3)  ·  Pain (3)  ·  Acute Pain (2)  ·  Emergencies (2)  ·  Graft vs Host Disease (2)  ·  Hematologic Diseases (2)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (73)  ·  Genetic Diseases, Inborn (73)  ·  Hemic and Lymphatic Diseases (73)  ·  Anemia, Hemolytic, Congenital (71)  ·  Hematologic Diseases (71)  ·  Anemia, Hemolytic (70)  ·  Anemia (69)  ·  Thalassemia (14)  ·  Iron Metabolism Disorders (10)  ·  Metabolic Diseases (10)  ·  Nutritional and Metabolic Diseases (10)  ·  Pathological Conditions, Signs and Symptoms (9)  ·  Signs and Symptoms (8)  ·  Neurologic Manifestations (7)

Interventions

Deferasirox (7)  ·  Deferiprone (6)  ·  Morphine (6)  ·  Hydroxyurea (5)  ·  Ketamine (5)  ·  Deferoxamine (4)  ·  Methotrexate (3)  ·  Mycophenolic Acid (3)  ·  Saline Solution (3)  ·  Tacrolimus (3)  ·  voxelotor (3)  ·  Basiliximab (2)  ·  Busulfan (2)  ·  Cyclophosphamide (2)  ·  Fentanyl (2)

Sponsors

Novartis Pharmaceuticals (10)  ·  ApoPharma (3)  ·  Duke University (3)  ·  Pfizer (3)  ·  Ain Shams University (2)  ·  Assistance Publique - Hôpitaux de Paris (2)  ·  Azienda Ospedaliera V. Cervello (2)  ·  Children's Hospital Medical Center, Cincinnati (2)  ·  Fakultas Kedokteran Universitas Indonesia (2)  ·  First Affiliated Hospital of Guangxi Medical University (2)  ·  Montefiore Medical Center (2)  ·  The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine (2)  ·  University of Pennsylvania (2)  ·  Agios Pharmaceuticals, Inc. (1)  ·  Ala'a Sharara (1)

Countries

United States (24)  ·  Egypt (9)  ·  China (7)  ·  Italy (7)  ·  Turkey (Türkiye) (6)  ·  France (5)  ·  Belgium (4)  ·  Brazil (4)  ·  Canada (4)  ·  Lebanon (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  Greece (3)  ·  India (3)  ·  Indonesia (3)

Top investigators

Fatma SE Ebeid, MD (2)  ·  Janet Kwiatkowski, MD (2)  ·  Yanfang Li, PhD (2)  ·  Yongrong Lai, MD (2)  ·  Alicia Chang, MD (1)  ·  Andrea Roe, MD MPH (1)  ·  Antonio Piga, M.D. (1)  ·  Arjunan Ganesh, MD (1)  ·  Aurelio Maggio, M.D. (1)  ·  Ayesha Khan, MBBS MPhil (1)  ·  Bamidele O Tayo, PhD (1)

Results publications

PMID 10100293, PMID 16273116, PMID 16737942, PMID 18298856, PMID 19236376, PMID 19407319, PMID 19724055, PMID 2082307, PMID 2666928, PMID 2689472, PMID 27288381, PMID 27537786, PMID 27993418, PMID 28238158, PMID 29155313, PMID 29756251, PMID 29794277, PMID 30663794, PMID 31723837, PMID 33025690, PMID 34847228, PMID 36018224, PMID 37247190, PMID 37807937, PMID 37975597, PMID 38401036, PMID 39428602, PMID 41730859, PMID 9620101

NIH funding

2014 (1), 2018 (1), R01HL175726 (1), U01NS129143 (1), U54HL070588 (1)